Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASD141 in advanced solid tumors
NCT06235437Phase 1Recruiting
- Sponsor
- Ascendo Biotechnology
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASD141 in metastatic solid tumor, sponsored by Ascendo Biotechnology. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events and Serious Adverse Events. Started Aug 2024; status: recruiting.
02
Drugs
ASD141
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT06235437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235437.